Recent research has explored the use of hematopoietic stem cell transplant (HSCT) in treating severe, refractory myasthenia gravis. This approach is being studied for its potential to improve outcomes in cases where other treatments have not been effective. The study focuses on successful HSCT applications in such scenarios, indicating a growing interest in innovative treatments for this condition.
The study by Li and Pike-Lee (2025) highlights the importance of exploring alternative treatments for refractory cases. While the details of the study are not fully disclosed, it suggests that HSCT could offer new hope for managing severe forms of the disease. Further research is likely needed to fully understand its potential benefits and limitations.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar 